PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 9, 2019

Primary Completion Date

October 24, 2022

Study Completion Date

October 24, 2022

Conditions

Acute Myeloid LeukemiaMyelodysplastic SyndromeMyelodysplastic/Myeloproliferative NeoplasmMyeloproliferative Neoplasm

Interventions

DRUG

Azacitidine

Given IV or SC

DRUG

BRD4 Inhibitor PLX51107

Given PO

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter